Printer Friendly

ANERGEN INC. REPORTS RESULTS

 ANERGEN INC. REPORTS RESULTS
 REDWOOD CITY, Calif., Feb. 20 /PRNewswire/ -- Anergen Inc.


(NASDAQ: ANRG) today reported a net loss of $3,893,000, or $.96 per share for the year ended Dec. 31, 1991, as compared to a loss of $3,005,000, or $1.01 per share for the year ended Dec. 31, 1990.
 The company's chief executive officer, John W. Fara, Ph.D., said, "Our results reflect increased activities in research programs and the initiation of pilot clinical trials for our therapeutic approach." The company completed its initial public offering of approximately 2 million shares in October, 1991, which provided the company with net proceeds of approximately $14.2 million.
 Anergen, headquartered in Redwood City, Calif., is developing proprietary therapies for treatment of autoimmune diseases using biopharmaceutical compounds that are designed to inactivate the specific T cells in the immune system responsible for such diseases. The company has conducted in vitro laboratory and in vivo studies which indicate that its compounds, called AnergiX (TM), may inactivate the specific T cells that cause the autoimmune diseases multiple sclerosis, myasthenia gravis and rheumatoid arthritis. Based on these laboratory results, Anergen is extending its ongoing research to the development of similar proprietary human-based AnergiX therapies.
 ANERGEN INC.
 Selected Financial Data
 (In thousands except per share data)
 Year Ended
 Dec. 31,
 1991 1990
 Operations Data
 Expenses:
 Research and Development $2,696 $2,014
 General and Administrative 1,218 900
 Interest, net (21) 127
 Net loss $3,893 $3,041
 Net loss per share $0.96 $1.01
 Shares used in calculating
 per share data 4,059 3,005
 ANERGEN INC.
 Balance Sheet Data
 Dec. 31, Dec. 31,
 1991 1990
 Cash and investments $13,655 $119
 Working capital 12,785 (332)
 Total assets 14,350 1,172
 Total liabilities 1,123 891
 Shareholders' equity 13,227 281
 -0- 2/20/92
 /CONTACT: John W. Varian or Joan A. Shields of Anergen 415-361-8901; or Elizabeth A. Gard or Roger S. Pondel of Rifkind Pondel & Parsons, 310-207-9300, for Anergen/
 (ANRG) CO: Anergen Inc. ST: California IN: MTC SU: ERN


KJ -- LA027 -- 1062 02/20/92 15:32 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 20, 1992
Words:353
Previous Article:McDONALD'S ANNOUNCES 64TH CONSECUTIVE QUARTERLY CASH DIVIDEND ON COMMON STOCK
Next Article:FOLIAGE PLUS ACQUIRES CABLE TELEVISION SYSTEM
Topics:


Related Articles
ANERGEN'S ANERGIX(TM) THERAPY FOR MYASTHENIA GRAVIS
ANERGEN INC. REPORTS FIRST QUARTER 1994 RESULTS
ANERGEN ANNOUNCES FINANCINGS TOTALING $8.7 MILLION
ANERGEN REPORTS FIRST QUARTER 1995 RESULTS
ANERGEN REPORTS THIRD QUARTER 1995 RESULTS
ANERGEN REPORTS 1995 FINANCIAL RESULTS
ANERGEN ANNOUNCES EXPANSION OF DIABETES COLLABORATION WITH CORPORATE PARTNER
Anergen Reports Second Quarter 1997 Results
Anergen Awarded Key Patent for Immune Assay Technology
Anergen Reports Third Quarter 1998 Results.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters